publication date: Nov. 30, 2018

Cancer groups: CMS proposal to lower drug prices would limit access for patients in “protected classes”

By Matthew Bin Han Ong

The Centers for Medicare and Medicaid Services has proposed a drug-pricing plan that administration officials say would offer lower cost options to seniors and provide support for the private sector to lower the cost of prescription drugs.

The Nov. 26 proposed rule was designed to meet the goals President Donald Trump set out in his Blueprint to Lower Drug Prices and Reduce Out-of-Pocket Costs document, published in May. The proposed rule is open for public comment through Jan. 25, 2019.

The proposed changes include:

Providing Part D plans with “greater flexibility” to negotiate discounts for drugs in protected therapeutic classes, so that beneficiaries who need these drugs will see lower costs.

Requiring Part D plans to increase transparency and provide enrollees and their doctors with a patient’s out-of-pocket cost obligations for prescription drugs when a prescription is written;

Codifying a policy similar to the one implemented for 2019 to allow “step therapy” in Medicare Advantage for Part B drugs, encouraging access to high-value products including biosimilars; and

Implementing a statutory requirement, recently signed by Trump, that prohibits pharmacy gag clauses—which originally prevented pharmacists from informing patients of cheaper alternatives—in Part D.

To access this members-only content, please log in.
If you're not a subscriber why not join today?
If you believe you should be able to view this area but cannot log in, then please contact us and we will try to rectify this issue as soon as possible.
To gain access to the members only content click here to subscribe.
You will be given immediate access to premium content on the site.
Click here to join.

Copyright (c) 2018 The Cancer Letter Inc.